Phlebitis

This category covers a range of thrombotic and embolic conditions relating to different areas of the venous system. Venous thrombosis is unusual in some respects, in that the

...


Read more on Phlebitis

 

 

Latest news articles

Added 2 months ago Drug news

Real-World data analysis of Eliquis for the treatment of venous thromboembolism in patients with active cancer.- BMS + Pfizer

The Bristol-Myers Squibb-Pfizer Alliance announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis...

Added 4 months ago Drug news

FDA approves Xarelto to help prevent blood clots in acutely ill medical patients.- BayerHealthCare + Janssen R&D

Bayer AG and its development partner Janssen Research & Development, LLC announced that the FDA has approved rivaroxaban (Xarelto) for...

Added 1 year ago Drug news

Phase III CASSINI study of Xarelto failed to meet endpoint in venous thromboembolism.- Janssen.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase III CASSINI study on the use...

Search all news articles for Phlebitis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fibrinogen Deficiency in Bleeding

Fibrinogen Deficiency in Bleeding

Fibrinogen is important for blood clot formation and breakdown. It is the first coagulant factor to be reduced to critical levels during massive trauma, cardiac surgery and postpartum haemorrhage that involve excessive bleeding. Persistent fibrinogen deficiency can lead to bleeding complications and an increased risk in mortality. This learning zone looks at both congenital and acquired fibrinogen deficiencies including indications and techniques for diagnosis, trigger level for treatment and treatment options.

Load more

Guidelines

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital.

Added 10 years ago

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R

The scope of this focused update of the 2014 AF Guideline includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section...

Added 6 months ago

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...

Added 1 year ago

Search all guidelines for Phlebitis
 

Journal articles

Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort

Severe postpartum haemorrhages (PPH) are responsible for maternal morbidity/mortality. Their complex management sometimes requires haemostatic supplementation, and therapeutic trials on fibrinogen or activated factor VII...

Added 2 months ago

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.

Added 6 months ago

Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.

Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic...

Added 6 months ago

Search all journal articles for Phlebitis
 

Clinical trials

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 2 years ago

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...

Added 6 years ago

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding...

Added 1 year ago

Search all clinical trials for Phlebitis
 

CME

Anticoagulation

Accrediting body
BJC Learning
Credits available
5
Registration required
1
Subscription fee
0

Starting patients on anticoagulants in secondary care: how to do it

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Starting patients on oral anticoagulants in primary care: how to do it

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Phlebitis